Concentrated IgG Formulation Stability and Local Tolerance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Concentrated immunoglobulin G (IgG) compositions for subcutaneous administration face challenges with stability and local tolerance due to the formation of oligomers and polymers, which can lead to anaphylactic reactions and hypotension, and the use of detergents can induce local reactions.
Innovation Solution
A formulation combining high concentrations of IgG with glycine and a nonionic detergent, such as polysorbate 80 or Pluronic F68, at specific low concentrations, ensuring stability and tolerance, with a physiological osmolality and minimal excipients like acetate, mannitol, or albumin.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If IgG concentration is increased to enable subcutaneous administration, then patient flexibility and independence are improved, but stability over time deteriorates with higher formation of oligomers and polymers
Solution Approach 1:
The patent introduces specific excipients (glycine at 20-50 mM and nonionic detergents at 0.01-0.1% w/v) as intermediary substances that mediate between the high IgG concentration and the stability requirement. These intermediaries prevent protein aggregation and maintain formulation stability without compromising the therapeutic effect of IgG.
Solution Approach 2:
The patent optimizes multiple formulation parameters simultaneously: IgG concentration (15-30% w/v), glycine concentration (20-50 mM), nonionic detergent concentration (0.01-0.1% w/v), and pH (4.5-5.5). By carefully adjusting these parameters within specific ranges, the formulation achieves both high concentration for subcutaneous use and adequate stability over time.
2Stability of the object's composition
If conventional detergents are used for intravenous administration, then IgG composition stability is improved, but local reactions are induced when administered subcutaneously
Solution Approach 1:
The patent selects nonionic detergents specifically suitable for subcutaneous administration based on their local tolerance properties. Different detergent types (polysorbates, poloxamers, triglycerides) are evaluated and selected based on their compatibility with subcutaneous tissue, ensuring both stability and minimal local reactions at the injection site.
3Quantity of substance
If high IgG concentration is formulated for subcutaneous use, then administration volume is reduced, but formation of protein aggregates increases due to thermal, mechanical or chemical stress
Solution Approach 1:
The formulation includes protective excipients (glycine and nonionic detergents) that are added beforehand to cushion against potential aggregation during storage and handling. These protective agents prevent protein-protein interactions that could lead to aggregate formation under thermal, mechanical, or chemical stress before administration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation achieves substantial stability and improved local tolerance, maintaining a low polymer content and osmolality, reducing the risk of adverse reactions and enhancing patient comfort for subcutaneous administration.
Implementation Method 1
the combination of nonionic detergent and glycine in such proportions contributes to a high stability of said formulation over time
Implementation Method 2
the concentrated immunoglobulin compositions according to the invention have a substantially physiological osmolality
Data Source
AI summary
The invention proposes the use of a pharmaceutical composition comprising 200 g/L immunoglobulin G (IgG), between 200 and 250 mM glycine and between 15 and 25 ppm nonionic detergent particularly suitable for subcutaneous administration. In addition, the pH of the composition is between 4.6 and 5.0.